Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment

07/16/2014 | 08:45pm US/Eastern
Recommend:
0

By a News Reporter-Staff News Editor at Cancer Weekly -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, announced it has entered into an agreement with Merck KGaA, Darmstadt, Germany, which operates as EMD Serono in the United States and Canada, to collaborate with Merck KGaA's biopharmaceutical division on the development and commercialization of a companion diagnostic (CDx) for an undisclosed target using Ventana's proprietary diagnostic assays. In alignment with Merck KGaA's strategic approach in personalized medicine, the aim is to develop a patient stratifying diagnostic test that can be used in multiple cancer indications. Merck KGaA, which is actively investing in innovation in the CDx field through a number of partnerships, will leverage Ventana's global leadership position in cancer diagnostics and vast expertise in CDx to achieve new levels of diagnostic clarity for the investigated target. As part of the agreement, Ventana will develop and validate the CDx and ensure its readiness, availability, and adherence to FDA and other health authority standards for future clinical trials (see also Ventana Medical Systems, Inc.).

"Tailoring therapies based on a patient's specific genes, proteins or tissue environment is a key expansion area for oncology. We are very pleased to partner with Merck in Darmstadt, Germany to co-develop a CDx that will play a vital role in improving the quality of care for cancer patients," said Doug Ward, Vice President, Companion Diagnostics, Ventana Medical Systems, Inc. "Ventana is committed to continuing to provide the industry's gold standard in biomarker detection using our proprietary assays as the basis for novel companion diagnostic tests."

This pharma partnership is one of several currently underway where the Ventana Companion Diagnostics team is delivering patient stratifying diagnostic tests that help identify those patients who are most likely to benefit from specific treatments. In addition to the biopharmaceutical division of Merck KGaA, Ventana has announced partnerships with Bayer, Pfizer, Boehringer Ingelheim, Takeda's Millennium unit, Genmab, Incyte, MedImmune and more. Since 2002, the company has worked with more than 45 biopharmaceutical partners and is currently engaged in more than 180 collaborative projects to develop and commercialize companion diagnostics globally.

Companion diagnostics (CDx) are tests designed to confirm the presence of a specific biomarker to assist physicians in selecting effective therapies for their patients, based on the individual characteristics of each person. Incorporating a companion diagnostic strategy into a drug development program may expedite the drug approval process and help generate more effective treatments with improved safety profiles for patients.

Keywords for this news article include: Cancer, Genetics, Oncology, Ventana Medical Systems Inc.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

(c) 2014 NewsRx LLC

Recommend :
0
React to this article
Latest news
Date Title
3m ago DECIMAL SOFTWARE : Organisational Changes
5m agoDJAsian Shares Weighed By China Data
7m ago Top 10 most used desktop instant messaging tools
8m ago AUDI : faces fine for price fixing
8m ago Powerful surge for success
8m ago VOLKSWAGEN : VW aid to children in quake-hit Yunnan
8m ago CHINA MERCHANTS BANK : Sport of kings a lure for nouveau riche
8m ago MTY NV : Private banking since 1667
8m ago FRASERS CENTREPOINT : Disclosure of Change in Interest of Substantial Unitholder (Schroders plc)
8m ago AMGEN : Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure
Latest news
Advertisement
Hot News 
DIXONS CARPHONE : *exane bnp raises dixons carphone price target to 450 (375) pence - 'outperform'
CONSORT MEDICAL : Says Voke Inhaler Gets Marketing Authorisation
AVEVA : Warns First Half Revenues Hit By Sterling, Contract Timing
NAIBU GLOBAL : Shares Plummet On Back Of Profit Drop, No Dividend Payout
CHINA GREEN AGRICULTURE : Reports Fiscal Year 2014 Financial Results
Most Read News
2h ago Heineken confirms, rebuffs SABMiller bid
2h ago Heineken confirms, rebuffs SABMiller bid
2h ago No sapphire? Huawei has got you covered
3h ago INTRA ENERGY : AAA completes Joint Venture
3h ago GOOGLE 'C' : Forget the desk: office designers put new emphasis on walking, talking and sharing: Apple, Google and BBC among employers leading a workplace revolution: No seat, no problem
Most recommended articles
5m agoDJAsian Shares Weighed By China Data
25m agoDJNorth Korea Sentences U.S. Citizen
1h agoDJU.K. Vows Action Against Islamic State
1h agoDJHeineken Rebuffs SABMiller Overture
1h agoDJSweden's Left Victorious in Elections
Dynamic quotes  
ON
| OFF